Continuous glucose monitoring (CGM) in people with type 2 diabetes not on multiple daily injections (MDI): review of current evidence and potential future positioning

Several studies have shown the clinical advantages of continuous glucose monitoring (CGM) in individuals with type 1 diabetes. As a result, the Joint Federal Committee (GBA) has recommended CGM systems for individuals with diabetes and intensified insulin therapy (ICT)/insulin pump therapy. Numerous randomized, observational, and retrospective studies have been conducted on the use of CGM in people with type 2 diabetes and non-intensified insulin therapy (BOT/SIT/CT) or therapy without insulin. This article provides a summary and discussion of the current evidence on the use of CGM in these patient groups. The studies indicate that CGM is effective in improving glycemic control and avoiding potential side effects of insulin therapy, such as hypoglycemia, even in individuals without intensified insulin therapy.